Harnessing Immuno-Oncology for the Management of Genitourinary Cancers
Evaluate approaches to manage immune-related adverse effects associated with immune checkpoint inhibitors in patients with genitourinary cancer, including renal cell and bladder cancer.
CME: 1.0
Integrating Multidisciplinary Care in the Diagnostic and Therapeutic Management of B-cell Non-Hodgkin Lymphomas
This webcast will examine the implications of B-cell NHLs as a disease, including accurate diagnosis, risk stratification and molecular biomarkers, to aid prognosis and treatment choice.
CME: 1.0
Follicular Lymphoma: Best Practices in the Therapeutic Management
Assess optimal time to initiate treatment for FL in order to delay disease progression and maintain patient quality of life
CME: 1.0
Enhancing Supportive Care for Pediatric Patients with High-Risk Neuroblastoma: A Focus on Nursing Practice Strategies
This activity is intended for oncology specialists who treat pediatric patients with high-risk neuroblastoma, such as physicians, physician assistants and social workers.
CME: 1.0
PARP in Practice: Expanding Options in the Maintenance Setting for Ovarian Cancer
Formulate management plans and review emerging strategies for adverse events associated with PARP inhibitors in the frontline, maintenance setting.
CME: 1.0
CDK 4/6 INHIBITION IN BREAST CANCER: SELF-STUDY MODULE II
This CME and CE activity will evaluate proper dosing administration, monitoring, and adherence strategies of CDK 4/6 inhibitors for the treatment of estrogen receptor–positive, HER2-negative advanced breast cancer.
CME: 1.0
Integration of Immunotherapy into Treatment for Hematological Malignancies
Identify strategies to incorporate immunotherapy into the treatment of appropriate patients with hematologic malignancies on the basis of current guidelines, safety and efficacy, and expert advice
CME: 3.5
Fungal Frontiers: Expert Decision Making in Medical Mycology
Define the role of emerging diagnostics in the management of invasive fungal disease (IFD)
CME: 2.0
Whiteboard Update: Transforming the Diagnosis and Treatment of Chronic Lymphocytic Leukemia
Develop individualized treatment plans for patients with CLL incorporating new agents based on genetic and molecular abnormalities, benefits and risks, comorbidities, and patient profiles
CME: 0.25

Hematology/Oncology